Broadening the scope of precision medicine: Diverse genetic data reveals thousands of new pharmacogenetic variants impacting patient care

A landmark study involving nearly 100,000 Americans has unveiled thousands of previously unidentified genetic variants that dictate how individuals process and respond to prescription medications. By leveraging the expansive and highly diverse dataset of the National Institutes of Health’s (NIH) All of Us Research Program, researchers have successfully mapped out a more inclusive landscape of "pharmacogenes"—the specific genes that influence drug metabolism, efficacy, and safety. This study, published Wednesday in Science Translational Medicine, marks a significant departure from historical genomic research, which has traditionally been heavily skewed toward populations of European ancestry.

The implications of these findings are profound. The study revealed that every single participant possessed at least one genetic variant in the 16 studied pharmacogenes, and perhaps more alarmingly, one in four participants had previously been prescribed a medication that could be directly impacted by these genetic predispositions. By uncovering variants that were previously obscured by a lack of diversity in genomic databases, this research provides a clearer roadmap for the future of precision medicine, ensuring that individualized clinical care is not a luxury afforded only to specific ethnic groups.

A New Standard for Genomic Diversity

For decades, the field of pharmacogenomics—the study of how genes affect a person’s response to drugs—has faced a "diversity gap." Major genomic repositories, such as the U.K. Biobank, have been instrumental in scientific discovery but often lack representation from non-European populations. Because genetic variants are not distributed evenly across human populations, these gaps have created a risk where clinical guidelines based on genomic data might be less accurate for patients from marginalized backgrounds.

The All of Us Research Program was specifically designed to rectify this imbalance. With the ambitious goal of recruiting one million participants from all walks of life across the United States, the program serves as a critical infrastructure for equitable health research. By mining this diverse data, researchers were able to identify variants that simply do not appear in conventional datasets. This discovery process underscores a fundamental truth in medicine: to provide universal precision care, one must first possess a universal understanding of the human genome.

The Mechanism of Pharmacogenomics

Pharmacogenes function as the body’s internal chemists. They encode the enzymes responsible for breaking down drugs, transporting them through the bloodstream, and managing their interaction with cellular receptors. When a patient possesses a variant in one of these genes, the "chemistry" of the drug interaction changes.

In some cases, a variant might cause a patient to metabolize a drug too quickly, rendering it ineffective because the medicine leaves the system before it can perform its therapeutic task. Conversely, a patient might metabolize a drug too slowly, leading to a toxic buildup of the substance in the bloodstream, which can trigger severe or life-threatening side effects. The variants identified in this study impact the clinical efficacy of common, high-stakes medications, including:

• Selective Serotonin Reuptake Inhibitors (SSRIs): Often used for depression and anxiety, where genetic factors can mean the difference between remission and treatment failure.
• Statins: Used for cholesterol management, where efficacy is highly dependent on individual metabolic rates.
• Chemotherapy Agents: Where precise dosing is essential to balance cancer cell destruction with the preservation of healthy tissue.
• Plavix (Clopidogrel): A common blood thinner that requires specific enzyme activity to be activated in the body.

Philip Empey, director of the Center for Clinical Pharmaceutical Sciences at the University of Pittsburgh and the study’s senior author, emphasized that these findings provide a scientific basis for what many patients have long suspected. "If you have a prior experience with a medicine that did not work for you, or had a side effect, we can’t say it’s absolutely because of genetics, but we are appreciating more and more that people are different, and genetics is one reason that may suggest where there may be differences," Empey noted.

The Hurdles to Clinical Integration

Despite the scientific promise, the path from a genomic discovery to a pharmacy counter is fraught with systemic, logistical, and financial obstacles. The researchers point to a "clinical translation gap," where the knowledge of a genetic variant does not necessarily translate into a change in a physician’s prescribing behavior.

Currently, several barriers impede the widespread adoption of pharmacogenetic testing:

1. Genome Access: A vast majority of the general population has not undergone whole-genome sequencing, meaning their "pharmacogenetic profile" remains unknown to their healthcare providers.
2. Provider Literacy: Physicians are often overwhelmed by the sheer volume of new medical information. Integrating complex genomic reports into a ten-minute primary care visit requires specialized decision-support tools that many health systems currently lack.
3. Fragmented Data: Genetic results are often stored in siloed reports rather than being integrated into the Electronic Health Record (EHR) in a way that provides real-time alerts to the prescribing physician.

Loren Saulsberry, a health policy researcher who has analyzed equity and pharmacogenomics, noted that while the study is a triumph for equity, it is only the first step. "This really furthers the emerging evidence of how genetically guided clinical care adds benefit across a diverse population," she stated. However, she warned that without deliberate policy efforts to integrate these findings into routine care, the "genomic divide" between those who receive tailored medicine and those who receive "one-size-fits-all" prescriptions will only widen.

The Funding Crisis: A Threat to Precision Health

The future of the All of Us Research Program, and by extension the future of this research, is currently under a cloud of fiscal uncertainty. The program relies on a combination of annual Congressional appropriations and funding from the 21st Century Cures Act, a 2016 law that provided a decade-long infusion of resources. As that funding source is set to expire in the 2027 fiscal year, the program is bracing for a significant budgetary contraction.

Current projections indicate that the program expects to receive roughly $122 million in funding once a budget is finalized—a staggering 80% decrease from its 2023 peak. This reduction has already triggered a cascade of operational cutbacks. Joshua Denny, who transitioned from the role of CEO of the program to a leadership position at the University of Chicago, described the "drastic" nature of these cuts.

"The engagement activities, the brick and mortar that we had enrolling at academic medical centers and FQHCs [Federally Qualified Health Centers] and mobile units… these kinds of things were cut back dramatically," Denny stated. Perhaps most concerning for the participants, the program has been forced to pause the return of genetic health-related results, a core benefit that encouraged thousands of individuals to volunteer their data.

Future Outlook and Pediatric Expansion

The program’s aspirations were not limited to adult populations. In 2023, All of Us launched an initiative to enroll children, aiming to build a longitudinal dataset that could inform pediatric health for generations. To date, approximately 5,000 children have been enrolled. However, these data remain in a developmental phase and are not yet available for broad research access.

Sara Van Driest, director of Pediatrics for All of Us, highlights the necessity of long-term stability. "In order to really enroll children at scale and build a dataset that’s going to fuel the future of precision health, we’re going to need stable funding in the years ahead. I should say, increased and stable funding in the years ahead," she said.

The success of the current study serves as both a testament to the power of the All of Us program and a warning of what is at stake. By identifying thousands of new variants, the study proves that the data exists to make medicine safer and more effective for everyone. However, the translation of this research into clinical reality depends on a sustained commitment to funding the infrastructure that collects, protects, and analyzes the human genome. As the medical community looks toward a future of precision health, the challenge remains to turn these genomic insights into a standard of care that is available to all, regardless of ancestry or socioeconomic status.